Phase III Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis: ORATORIO Study Design

被引：0
作者：
Montalban, Xavier
Wolinsky, Jerry
Yin, Ming
Leppert, David
Glanzman, Robert
Chin, Peter
机构：
来源：
NEUROLOGY | 2011年 / 76卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A319 / A320
页数：2
相关论文
共 50 条
[1]   Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive Multiple Sclerosis from the Phase III ORATORIO Study [J].
Kappos, L. ;
Montalban, X. ;
Hauser, S. L. ;
Julian, L. ;
Manfrini, M. ;
Belachew, S. ;
Model, F. ;
Hubeaux, S. ;
Bar-or, A. ;
Wolinsky, J. S. .
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 :431-431
[2]   Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study [J].
Fox, E. J. ;
Markowitz, C. ;
Applebee, A. ;
Montalban, X. ;
Wolinsky, J. S. ;
Belachew, S. ;
Fiore, D. ;
Han, J. ;
Musch, B. ;
Giovannoni, G. .
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 :658-659
[3]   OCRELIZUMAB IN PRIMARY PROGRESSIVE MS: THE ORATORIO STUDY [J].
Giovannoni, G. ;
Arnold, D. L. ;
Bar-Or, A. ;
de Seze, J. ;
Hemmer, B. ;
Montalban, X. ;
Rammohan, K. ;
Wolinsky, J. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (12)
[4]   Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis [J].
Montalban, X. ;
Hemmer, B. ;
Rammohan, K. ;
Giovannoni, G. ;
de Seze, J. ;
Bar-Or, A. ;
Arnold, D. ;
Sauter, A. ;
Leppert, D. ;
Chin, P. ;
Garren, H. ;
Messier, M. ;
Wolinski, J. ;
Kakarieka, A. ;
Masterman, D. .
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 :706-706
[5]   EFFECT OF OCRELIZUMAB ON UPPER LIMB FUNCTION IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN THE ORATORIO STUDY (ENCORE) [J].
Fox, Edward ;
Markowitz, Clyde ;
Applebee, Angela ;
Montalban, Xavier ;
Wolinsky, Jerry S. ;
Belachew, Shebeshih ;
Fiore, Damian ;
Han, Jian ;
Musch, Bruno ;
Giovannoni, Gavin .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06) :E14-E14
[6]   Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study [J].
Montalban, X. ;
Hemmer, B. ;
Rammohan, K. ;
Giovannoni, G. ;
de Seze, J. ;
Bar-Or, A. ;
Arnold, D. L. ;
Sauter, A. ;
Kakarieka, A. ;
Masterman, D. ;
Chin, P. ;
Garren, H. ;
Wolinsky, J. .
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 :781-782
[7]   Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study [J].
Montalban, Xavier ;
Hemmer, Bernhard ;
Rammohan, Kottil ;
Giovannoni, Gavin ;
De Seze, Jerome ;
Bar-Or, Amit ;
Arnold, Douglas ;
Sauter, Annette ;
Masterman, Donna ;
Fontoura, Paulo ;
Garren, Hideki ;
Chin, Peter ;
Wolinsky, Jerry .
NEUROLOGY, 2016, 86
[8]   Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis [J].
de Seze, J. ;
Montalban, X. ;
McDougall, F. ;
Sauter, A. ;
Deol-Bhullar, G. ;
Wolinsky, J. .
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 :677-678
[9]   Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis [J].
de Seze, Jerome ;
Montalban, Xavier ;
McDougall, Fiona ;
Julian, Laura ;
Sauter, Annette ;
Deol-Bhullar, Gurpreet ;
Wolinsky, Jerry .
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) :84-84
[10]   Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial [J].
Fox, Edward J. ;
Markowitz, Clyde ;
Applebee, Angela ;
Montalban, Xavier ;
Wolinsky, Jerry S. ;
Belachew, Sihbeshih ;
Fiore, Damian ;
Pei, Jinglan ;
Musch, Bruno ;
Giovannoni, Gavin .
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (14) :1862-1870
12345